These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36793715)

  • 21. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Raethke M; van Hunsel F; Thurin NH; Dureau-Pournin C; Mentzer D; Kovačić B; Mirošević Skvrce N; De Clercq E; Sabbe M; Trifirò G; Luxi N; Giovanazzi A; Shakir S; Klungel OH; Schmikli S; Sturkenboom M
    Drug Saf; 2023 Apr; 46(4):391-404. PubMed ID: 37024736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
    Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
    JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
    Kim S; Bea S; Choe SA; Choi NK; Shin JY
    Eur J Clin Pharmacol; 2024 Mar; 80(3):445-453. PubMed ID: 38212538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.
    Noh Y; Ko HY; Kim JH; Yoon D; Choe YJ; Choe SA; Jung J; Shin JY
    Epidemiol Health; 2023; 45():e2023054. PubMed ID: 37309115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
    Gandhi AP; Venkatesh U; Murali N
    Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmarketing Safety Monitoring After Influenza Vaccination Using a Mobile Health App: Prospective Longitudinal Feasibility Study.
    Nguyen MTH; Krause G; Keller-Stanislawski B; Glöckner S; Mentzer D; Ott JJ
    JMIR Mhealth Uhealth; 2021 May; 9(5):e26289. PubMed ID: 33960950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
    Oosterhuis I; Scholl J; van Puijenbroek E; Kant A; van Hunsel F
    Drug Saf; 2023 Jan; 46(1):65-75. PubMed ID: 36350465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial.
    Tsafack M; Ateudjieu J
    Pan Afr Med J; 2015; 22():351. PubMed ID: 26985269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
    Rolfes L; Härmark L; Kant A; van Balveren L; Hilgersom W; van Hunsel F
    Vaccine; 2022 Feb; 40(7):970-976. PubMed ID: 35067381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
    Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
    Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
    Hamilton E; Oversby S; Kitchener S; Ratsch A
    Aust N Z J Public Health; 2022 Dec; 46(6):738-744. PubMed ID: 36190203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Torp Hansen K; Kusk Povlsen F; Hammer Bech B; Nygaard Hansen S; Ulrikka Rask C; Fink P; Jørgensen T; Nielsen H; Meinertz Dantoft T; Marie Thysen S; Rytter D
    Vaccine; 2023 Jul; 41(33):4879-4887. PubMed ID: 37391313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
    Amdany H; Koech B
    JBI Evid Implement; 2023 Jun; 21(2):146-155. PubMed ID: 36545897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess.
    Yamoah P; Mensah KB; Attakorah J; Padayachee N; Oosthuizen F; Bangalee V
    Hum Vaccin Immunother; 2022 Nov; 18(6):2109365. PubMed ID: 35947052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.
    Puspitarani F; Sitaresmi MN; Ahmad RA
    Front Public Health; 2022; 10():999354. PubMed ID: 36388348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.